This phase 2, double-blind SAVITRI study included 183 adults 18 to 65 years old, randomized into placebo, osavampator 1 mg, and osavampator 3 mg groups. At day 56, osavampator 1 mg maintained significance in reduction, while osavampator 3 mg showed favorable but ultimately nominal difference in reduction. Remission rates (MADRS total score of 10 or less) were statistically significant in the 1 mg osavampator group, while the 3 mg osavampator group showed numerical improvement but not statistical significance. Other reported adverse effects in groups receiving osavampator include insomnia (n=1 (1 mg group), n=3 (3 mg group)), somnolence (n=3 (1 mg group)), and nausea (n=1 (1 mg group)). Neurocrine Biosciences presents positive new data from phase 2 study of osavampator in adults with major depressive disorder.